赛升药业：子公司达格列净二甲双胍缓释片上市许可申请获受理

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical has received a notice from the National Medical Products Administration regarding the acceptance of its application for the production registration of Dapagliflozin Metformin Extended-Release Tablets [2] Group 2 - The announcement was made on the evening of December 4, indicating a significant step in the company's product development process [2] - The product in question, Dapagliflozin Metformin Extended-Release Tablets, is aimed at the domestic market, highlighting the company's focus on local production and regulatory compliance [2] - This development may enhance the company's portfolio in the diabetes treatment segment, potentially leading to increased market share and revenue growth [2]